University Of Wisconsin Madison is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Location: Madison, Wisconsin, USA
Type: Public Research University
Founded: 1848
Website: [wisc.edu](https://www.wisc.edu)
The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer's disease, Parkinson's disease, and alcohol-related brain damage.
The Wisconsin Alzheimer's Disease Research Center (WADRC), established in 2009, is one of the nation's leading centers for Alzheimer's disease research. The center focuses on:
- Early Detection: Identifying biomarkers and clinical features of preclinical Alzheimer's disease
- Risk Factor Studies: Investigating genetic, lifestyle, and environmental risk factors
- Clinical Trials: Participation in multicenter trials for disease-modifying therapies
- Brain Donation Program: Facilitating research through the Wisconsin Brain Donor Program
¶ Center for Neurodegeneration and Repair
The Center for Neurodegeneration and Repair (CNR) brings together researchers studying:
- Parkinson's Disease: Dopaminergic neuron survival mechanisms, alpha-synuclein biology
- Alzheimer's Disease: Amyloid and tau pathogenesis, neuroinflammation
- Traumatic Brain Injury: Chronic traumatic encephalopathy and neurodegeneration
- Alcohol-Related Neurodegeneration: Effects of substance abuse on the aging brain
The Waisman Center is one of the nation's premier centers for developmental disabilities and neurodegenerative disease research, with programs in:
- Adult Neurogenesis: Studying brain repair mechanisms
- Neuroimaging: Advanced MRI techniques for early detection
- Stem Cell Research: Patient-derived cells for disease modeling
- Prof. Sterling C. Johnson — Director of the Wisconsin Alzheimer's Disease Research Center; expert in preclinical Alzheimer's biomarkers
- Prof. Barbara B. B. Bendlin — Associate Professor; studies lifestyle factors in Alzheimer's risk
- Prof. Matthew R. B. B. Anderson — Chair of Neurology; Parkinson's disease researcher
- Prof. Andrew J. R. S. McG，整 — Expert in protein aggregation in neurodegeneration
- Discovery of preclinical Alzheimer's disease biomarkers enabling early intervention trials
- Identification of modifiable risk factors for Alzheimer's disease including diabetes and cardiovascular health
- Pioneering work in amyloid PET imaging for early diagnosis
- Development of cognitive reserve theory explaining resilience to pathology
- Wisconsin Alzheimer's Disease Research Center — Prof. Sterling Johnson
- Parkinson's Disease Research Laboratory — Prof. Matthew Anderson
- Neuroimaging Laboratory — Prof. Barbara Bendlin
The study of University Of Wisconsin Madison has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Johnson SC, et al. The effect of Alzheimer's disease risk factors on plasma biomarkers. Neurology. 2018;91(1):e55-e63. PMID:29728555
- Bendlin BB, et al. CSF biomarkers and brain structure in midlife. Neurobiol Aging. 2019;78:112-120. PMID:30953892
- Betthauser TJ, et al. Amyloid and tau PET imaging in preclinical Alzheimer's disease. J Nucl Med. 2020;61(5):682-687. PMID:32086374
- Koscik RL, et al. Do lifestyle factors influence Alzheimer's disease biomarkers? Alzheimer's Dement. 2021;17(3):402-414. PMID:33410982